

 JASN [®] Journal of the American Society of Nephrology				
2006 JASN IMPACT FACTOR 7.371		HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP		
<input type="text"/> <input type="button" value="GO"/> advanced		CURRENT ISSUE	ARCHIVES	JASN EXPRESS
		ONLINE SUBMISSION		

Published ahead of print on November 21, 2007

J Am Soc Nephrol 19: 102-108, 2008

© 2008 American Society of Nephrology

doi: 10.1681/ASN.2007060688

Basic Research

Vasopressin Directly Regulates Cyst Growth in Polycystic Kidney Disease

Xiaofang Wang, Yanhong Wu, Christopher J. Ward,
Peter C. Harris and Vicente E. Torres

Mayo Clinic College of Medicine, Rochester, Minnesota

Correspondence: Dr. Vicente E. Torres, Division of Nephrology and Hypertension, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. Phone: 507-284-7572; Fax: 507-266-9315; E-mail: torres.vicente@mayo.edu

Received for publication June 20, 2007. Accepted for publication August 2, 2007.

The polycystic kidney diseases (PKD) are a group of genetic disorders causing renal failure and death from infancy to adulthood. Arginine vasopressin (AVP) V2 receptor antagonists inhibit cystogenesis in animal models of cystic kidney diseases, presumably by downregulating cAMP signaling, cell proliferation, and chloride-driven fluid secretion. For confirmation that the protective effect of these drugs is due to antagonism of AVP, PCK (*Pkhd1*^{-/-}) and Brattleboro (*AVP*^{-/-}) rats were crossed to generate rats with PKD and varying amounts of AVP. At 10 and 20 weeks of age, PCK *AVP*^{-/-} rats had lower renal cAMP and almost complete inhibition of cystogenesis compared with PCK *AVP*^{+/+} and PCK *AVP*^{+/-} rats. The V2 receptor agonist 1-deamino-8-d-arginine vasopressin increased renal cAMP and recovered the full cystic phenotype of PCK *AVP*^{-/-} rats and aggravated the cystic disease of PCK *AVP*^{+/+} rats but did not induce cystic changes in wild-type rats. These observations indicate that

This Article

- ▶ [Full Text](#)
- ▶ [Full Text \(PDF\)](#)
- ▶ [Supplemental Data](#)
- ▶ **All Versions of this Article:**
[ASN.2007060688v1](#)
19/1/102 *most recent*
- ▶ [Alert me when this article is cited](#)
- ▶ [Alert me if a correction is posted](#)
- ▶ [Citation Map](#)

Services

- ▶ [Email this article to a friend](#)
- ▶ [Similar articles in this journal](#)
- ▶ [Similar articles in PubMed](#)
- ▶ [Alert me to new issues of the journal](#)
- ▶ [Download to citation manager](#)
- ▶ [© Get Permissions](#)

Citing Articles

- ▶ [Citing Articles via HighWire](#)

Google Scholar

- ▶ [Articles by Wang, X.](#)
- ▶ [Articles by Torres, V. E.](#)

PubMed

- ▶ [PubMed Citation](#)
- ▶ [Articles by Wang, X.](#)
- ▶ [Articles by Torres, V. E.](#)

Related Collections

- ▶ [Related Articles](#)

AVP is a powerful modulator of cystogenesis and provide further support for clinical trials of V2 receptor antagonists in PKD.

Related Articles

This Month's Highlights

J. Am. Soc. Nephrol. 2008 19: 13. [[Full Text](#)]

Therapy for Polycystic Kidney Disease? It's Water, Stupid!

Jared J. Grantham

J. Am. Soc. Nephrol. 2008 19: 1-7. [[Full Text](#)]

This article has been cited by other articles:



Journal of the American Society of Nephrology

[▶ HOME](#)

J. J. Grantham

Therapy for Polycystic Kidney Disease? It's Water, Stupid!

J. Am. Soc. Nephrol., January 1, 2008; 19(1): 1 - 7.

[[Full Text](#)] [[PDF](#)]

[HOME](#) | [CURRENT ISSUE](#) | [ARCHIVES](#) | [JASN Express](#) | [ONLINE SUBMISSION](#) | [AUTHOR INFO](#)
[EDITORIAL BOARD](#) | [SUBSCRIBE](#) | [FEEDBACK](#) | [ALERTS](#) | [HELP](#)

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673